Advertisement
U.S. markets open in 5 hours 29 minutes

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
13.32-0.11 (-0.82%)
At close: 04:00PM EDT
13.18 -0.14 (-1.05%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close13.43
Open13.45
Bid0.00 x 1400
Ask0.00 x 4000
Day's Range13.30 - 13.51
52 Week Range7.09 - 13.93
Volume4,137,290
Avg. Volume10,844,593
Market Cap14.976B
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 27, 2017
1y Target Est15.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
16% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for TEVA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Teva Pharmaceutical Industries
    Analyst Report: Teva Pharmaceutical Industries LimitedTeva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.
    Rating
    Fair Value
    Economic Moat
    22 days agoMorningstar
View more
  • The Wall Street Journal

    Now That Two Inhaler Makers Are Capping Patient Costs, Will More Follow?

    AstraZeneca’s move on Monday to cap at $35 the out-of-pocket costs that patients pay for the company’s Symbicort inhaler speaks to the political and regulatory pressure coming to bear on manufacturers of certain commonly used but expensive treatments. The British drugmaker’s shift follows a similar step last month by Boehringer Ingelheim, which sells rival inhalers including Atrovent and Spiriva. Sen. Bernie Sanders, the independent from Vermont, launched an investigation of inhaler prices in January.

  • GuruFocus.com

    EVP, CFO Eliyahu Kalif Sells 77,550 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

    Eliyahu Kalif, Executive Vice President and Chief Financial Officer of Teva Pharmaceutical Industries Ltd (NYSE:TEVA), has sold 77,550 shares of the company on March 6, 2024, according to a recent SEC filing.

  • Business Wire

    Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

    SHANGHAI & TEL AVIV, Israel, February 26, 2024--Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd ("Nhwa") today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington’s disease (HD) and tardive dyskinesia (TD) in adults. The pa